Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Secukinumab (Cosentyx) is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, active ankylosing spondylitis, and non-radiographic axial spondyloarthritis with objective signs of inflammation. It is also used in treating adults with enthesitis-related arthritis.
• Fifty-eight systematic reviews/meta-analyses were reviewed to gather information about Secukinumab.
• In terms of efficacy and safety, Secukinumab ranked highest in achieving clear/minimal disease activity in Palmoplantar Psoriasis compared to other treatments. For Palmoplantar Pustulosis, the data were less definitive across treatments, but Secukinumab showed promising outcomes.
• When treating Psoriatic Arthritis, Secukinumab demonstrated superior efficacy along with infliximab and adalimumab at a 6-month follow-up period. The safety profile was consistent, suggesting it as an acceptable alternative compared to other treatments.
• For Moderate-to-Severe Psoriasis patients, direct and indirect comparisons revealed that Secukinumab, along with interleukin inhibitors like ixekizumab, showed superior efficacy in achieving PASI 90 responses, indicating significant skin clearance potential.
• In cases involving Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis conditions; effectiveness and safety were observed, with treatments showing improvements on ASAS20/40 response rates as well as physical function over varying trial durations, which underlines its utility for long-term management purposes.
• Nail Psoriasis can be effectively managed using various biologics, including Secukinumab, although it did not emerge as the absolute leader based on all parameters, hence choice could be tailored according to patient needs or specific disease manifestations.
• Secukinumab consistently displayed favorable safety profiles across different indications, often ranking among top treatments especially for achieving clear or almost clear skin in Psoriasis and treating Psoriatic Arthritis with a good balance between efficacy and safety. It also showed significant patient improvement without raising major safety concerns when managing Ankylosing Spondylitis and non-radiographic axial Spondyloarthritis.
• While Secukinumab's overall performance across the general population afflicted with the mentioned conditions is robust, there was no thorough analysis of subgroup considerations such as age, sex, or ethnicity that allows for granular conclusions.
• The drug has shown to be effective both in patients previously untreated with biologics and in biologic-experienced populations, suggesting it is a viable first-line treatment option and an effective alternative for those who have failed other biologic therapies.